Acthar® Gel (repository corticotropin injection) Reference Bibliography

This bibliography contains verifiable peer-reviewed manuscripts and abstracts on the use of Acthar Gel, as well as publications supported by Mallinckrodt that relate to Acthar directly or indirectly. Human and preclinical studies, health economic and outcomes analyses (HEOR), reports and reviews are included and, where available, links to PubMed are provided.

Updated: November 2019

Nephrology


### Nephrology HEOR


### Neurology


Neurology – HEOR


Bryan M, Sergott RC. Change in visual acuity and retinal structures following Repository Corticotropin Injection (RCI) therapy in patients with acute demyelinating optic neuritis: Improvement in low contrast visual acuity in both affected and contralateral eyes in a single-armed open-label study. *J Neurol Sci*. 2019; [published online: October 22, 2019](#)


Pulmonology


Pulmonology – HEOR


Rheumatology


238. Fiechtner JJ, Montroy T, June J, Huyhn-Duc J. A single-site, investigator-initiated, open-label trial of the adrenocorticotropic hormone analog H.P. Acthar Gel (repository corticotropin

239. Fiechtner JJ, Montroy T. Treatment of moderately to severely active systemic lupus erythematosus with adrenocorticotropic hormone: a single-site, open-label trial. Lupus. 2014;23(9):905-912. Link


255. Gaylis N, Needell S, Sagliani J. The effect of corticotropin (ACTH 80 units weekly or biweekly) in combination with MTX in newly diagnosed RA patients from a clinical and structural perspective as measured by a CDAI score and osteitis, synovitis, and erosions on MRI [EULAR abstract AB0503]. *Ann Rheum Dis.* 2015;74(suppl 2):1066-1067


257. Gillis TM, Crane M, Hinkle C, Wei N. H.P. Acthar® Gel (repository corticotropin injection) as adjunctive therapy in patients with rheumatoid arthritis who have failed at least three biologic therapies with different modes of action [EULAR abstract AB0502]. *Ann Rheum Dis.* 2015;74(suppl 2):1066-1066


279. Wu A, June J. Case series: Comparison of repository corticotropin injection (H.P. Acthar Gel) versus glucocorticoids on bone density in SLE patients [ACR abstract 331]. Arthritis Rheumatol. 2017;69(supp 10): 452

280. Zutshi DW, Friedman M, Ansell BM. Corticotrophin therapy in juvenile chronic polyarthritis (still's disease) and effect on growth. Arch Dis Child. 1971;46(249):584-593. [Link](#)

**Rheumatology – HEOR**


Baram TZ. What are the reasons for the strikingly different approaches to the use of ACTH in infants with West Syndrome? *Brain and Development.* 2001;7:647-648. [Link](#)


Berkovich RR. Acute Multiple Sclerosis Relapse. *Continuum (Minneap Minn).* 2016;22(3):799-814. [Link](#)


334. Decker D, Higgins P, Bendele A, Becker P. Repository corticotropin injection (H.P. Acthar® Gel) attenuates established collagen-induced arthritis when used alone or as adjuvant therapy with Etanercept (Enbrel®) [AAI abstract THER5P.902]. *J Immunol*. 2015;194(suppl 1):139.4-139.4


349. Hogan JJ, Jai R, Gerald BA, Andrew SB, Pietro AC, Maya KR. Treatment of resistant primary focal segmental glomerulosclerosis (FSGS) with adrenocorticotropic hormone (ACTH) gel [ASN abstract SA-PO381]. *J Am Soc Nephrol*. 2012;23(suppl):725A


351. Jensen MA, Abraham P, Reder AT, Arnason BGW. Co-production of GM-CSF, IL-22, or IL-17F identifies a pathogenic high IL-17A-producing T cell subset from MS patients that is steroid resistant [ANA abstract S151]. *Ann Neurology*. 2016;80:S53-S54.

352. Kater CE, Irony I, Biglieri EG, Faical S. Continuous adrenocorticotropic administration in hypopituitarism produces asynchronous increases of deoxycorticosterone and 11-
deoxycortisol relative to other reduced zona fasciculata steroids. J Clin Endocrinol Metab. 1990;71(2):305-310. Link


368. Lisak R, Nedelkoska L, Benjamins J. ACTH1-39 protection of oligodendrocytes from damage relevant to multiple sclerosis involves both direct and indirect mechanisms. [AAN abstract P2.189]. Neurology. 2015;84(suppl 14):P2.189


371. Lisak R, Nedelkoska L, Touil H, Bar-Or A, Benjamins J. Sigma 1 receptor and melanocortin receptor agonists protect oligodendroglia from death induced by products of B cells from multiple sclerosis patients. [ECTRIMS abstract P582]. Mult Scler. 2018;24(S2):280


Montroy T, Fiechtner JJ. A single-site, investigator initiated, open-label trial of the adrenocorticotropic hormone (ACTH) analogue H.P. Acthar Gel (repository corticotropin injection) among subjects with moderately to severely active systemic lupus erythematosus (SLE) [EULAR abstract AB0382]. Ann Rheum Dis. 2013;72(suppl 3):904


Obi O, Judson M, Maier L, Wells A, Baughman R. Role of baseline dyspnea index (BDI) and transition dyspnea index (TDI) as a measure of self-reported health related quality of life in sarcoidosis patients [ATS abstract A5609]. Am J Respir Crit Care Med. 2019;199:A5609.


There is a vast body of clinical data in the peer-reviewed literature regarding the therapeutic use of Acthar® Gel (repository corticotropin injection). For more information, please contact our Medical Information Group by phone at 800.844.2830, by fax at 913.451.6409, or by email at medinfo@mnk.com